|
|
||||||||
Ann Thorac Surg 1999;68:149-153
© 1999 The Society of Thoracic Surgeons
a Division of Pediatric CardiologyMedical College of Georgia, Augusta, Georgia, USA
b Department of Cardiovascular Radiology, University of Minnesota, Minneapolis, Minnesota, USA
Address reprint requests to Dr Amin, Division of Pediatric Cardiology, Medical College of Georgia, 1120 15th St, BAA 800 W, Augusta, GA 30912
e-mail: zamin{at}mail.mcg.edu
Presented at the Thirty-fifth Annual Meeting of The Society of Thoracic Surgeons, San Antonio, TX, Jan 2527, 1999.
| Abstract |
|---|
|
|
|---|
Methods. Five Yucatan pigs with naturally occurring PVSD (3- to 7-mm diameter) and 5 dogs with surgically created MVSD (6- to 14-mm diameter) were subjects of this study. The VSDs were closed intraoperatively with a 7-French delivery sheath inserted through the free wall of the right (n = 5) or left ventricle (n = 5), under epicardial echocardiogram guidance. The animals were followed for 3 months.
Results. There was no operative mortality. All MVSD closed after placement of the device. Closure rate of PVSD was 4 of 5 after placement and 3 of 5 after 3 months. One pig developed aortic incompetence at the last follow-up.
Conclusions. Perventricular closure of MVSD and PVSD is feasible. Avoidance of CPB can decrease recovery time, its complications, and trauma to the femoral vessels.
| Introduction |
|---|
|
|
|---|
| Material and methods |
|---|
|
|
|---|
The devices
The PVSD and MVSD devices were modified from the Amplatzer Atrial septal occluder (AGA Medical, Golden Valley, MN) [4, 5]. Both devices were constructed from 0.004-inch wire mesh (Nitinol). The wires were laser welded and then braided with heat treatment. The device was woven to form two discs with a connecting waist. Important features of the device are that it is self-expandable, self-centering, and retrievable, has a low profile, and can be delivered through a 6- or 7-French sheath. It has a microscrew on one (right or left) disc for attachment to the delivery cable. The steps involved in loading and deployment of the device have been discussed elsewhere [4, 5].
MVSD device
The diameter of the device waist corresponded to the size of the VSD, and the length of the waist to the thickness of the ventricular septum. The right and left ventricular discs were of the same size. The flange size measured approximately 7 mm (Fig 1A). The discs and the connecting waist were filled with polyester fiber to enhance thrombogenicity. The device has already been used for percutaneous closure of muscular VSD [6].
|
Animal model
The animal model consisted of 5 adult mongrel dogs weighing 2029 kg and 5 pigs weighing 1825 kg.
Creation and closure of muscular ventricular septal defects
The method employed in the creation of muscular ventricular septal defects has been discussed elsewhere [6, 7]. Briefly, under general endotracheal anesthesia, the chest was entered via median sternotomy. A sharp punch was used to create the defect through a limited right ventriculotomy. The size of the defect was measured with the help of an epicardial echocardiogram. It ranged from 6 to 14 mm. Three defects were located in the midmuscular septum, one in the anterior muscular, and one in the apical septum.
To close the MVSD, a 7-French delivery sheath with the dilator was pushed through the free wall of right ventricle and aimed toward the VSD (Fig 2). The sheath was advanced across the VSD and the dilator was removed. The device was screwed onto the delivery cable, and was advanced through the sheath to the left ventricle. After confirming its position by epicardial echocardiogram, the delivery cable was pushed and the left disc was deployed. The sheath and the delivery cable were pulled until the left disc approximated the ventricular septum. The delivery cable was kept stable and the sheath was withdrawn to deploy the right ventricular disc. The position of the device was rechecked by echocardiogram, and the device was disconnected from the cable by counterclockwise rotation (Fig 3). The pericardium was partially approximated. A mediastinal and, if needed, pleural chest tubes were placed. The sternum was closed in the standard fashion. The animal was extubated in the operating room. Intravenous fluids were maintained until oral intake was adequate. Intravenous antibiotics and analgesia were provided for 3 days.
|
|
Under general endotracheal anesthesia, the animal was placed on the operating table with its left side up. Using aseptic technique, the left chest was prepped and draped. A transverse incision was made and the chest was entered through the fourth intercostal space. The pleura was incised, and the lung was retracted with the help of malleable retractors. The pericardium was opened parallel to the phrenic nerve, and stay sutures were applied to retract the pericardium. An epicardial echocardium was performed to delineate the size of the defect and to measure the distance from the superior edge of the VSD to the aortic valve (Fig 4).
|
|
|
Pathology
The heart and the lungs were removed and sent for gross pathologic examination.
| Results |
|---|
|
|
|---|
PVSD
Perventricular closure of PVSD was attempted in 5 pigs. Placement was successful in all animals. The closure rate was 80% immediately after deployment and 60% (3 of 5) after 3 months.
Mild tricuspid regurgitation developed in 3 pigs. Aortic valve remained competent in 4 of 5 pigs at 3 months follow up (Fig 7). There were no occurrences of atrial arrhythmia, ventricular arrhythmia, or heart block. One pig developed residual VSD at the 3-month follow-up.
|
Paramembranous VSD pathology
Gross pathologic examination of the heart revealed the device covered with neoendocardium. In 1 pig, organized clot was seen at the inferior margin of the left ventricular side of the device. In 2 other pigs, the microscrew on the left and right ventricular side was not covered with neoendocardium, although the disc was completely covered. The results were comparable with our previous report, where percutaneous technique was used to close PVSD [8].
In the pig that developed aortic insufficiency, the aortic rim of the concentric device was found to impinge upon the noncoronary cusp of the aortic valve. The device had tilted from its original position.
| Comment |
|---|
|
|
|---|
In a previously published report of intraoperative closure of VSD on CPB bypass [10], the results were disappointing because of high mortality and residual defects. Transesophageal or epicardial echocardiography was of little help to assess residual shunt in a flaccid heart. The delivery system used by the authors was rigid and the device was not self-centering, whereas, the delivery system of the Amplatz VSD device is relatively flexible and small (6 or 7-F). The shape of the device is circular, it closes the defect by stenting the hole, and therefore oversizing is not required. There is no danger of disc separation and the flange size is small (5 to 7 mm).
The mortality rate after repair of isolated VSD approaches zero [11]. However, the mortality can be as high as 30% if the defects are multiple or associated with other cardiac anomalies [12]. In some recent studies, location of the defect and residual shunts were significant risk factors for intraoperative death and reoperation [13, 14]. Perventricular technique is a simplified way of approaching difficult to close residual defects.
The primary difference between the previous and this study is that the defects were closed directly through the free wall of the ventricle without CPB. This technique decreases the chance of major complications should the device embolize during the procedure. There is no exposure to radiation and the procedure time is short. In infants, percutaneous catheter closure of septal defects is difficult because suitable catheters are not yet available. In one study [15], attempted closure of PVSD and MVSD resulted in a failure rate of 28%. The youngest patient was 4 years old, although the delivery system was 79-F. Other devices may require larger delivery system making catheter closure undesirable.
In this series, closure of PVSD through the left ventricle was successfully accomplished via left thoracotomy. This step will help avoid CPB and possibly a future operation in patients who have coarctation of aorta with VSD. Results of paramembranous VSD closure were disappointing because of incomplete endothelialization and residual shunt in 2 pigs. These results are comparable with other series [16]. The following factors may have contributed to these results. (1) The thickness of the rim around the VSD is uneven, which may make the device unstable. (2) Chordal attachment on the right ventricular side can hinder expansion of the right disc and pull the waist of the device toward the right ventricle. This may result in residual shunt. (3) The length of the waist of the device was larger than the thickness of the septum, separating the discs from the septum. This probably led to incomplete endothelialization and tilting of the device. (4) None of these animals received aspirin or any other antiplatelet medication that may have contributed to clot formation on one device. We strongly believe that after placement of the device, aspirin therapy should be initiated for at least 6 months to prevent thromboembolization. (5) The design of the device may have influenced our results. Since two types of PVSD devices (eccentric and concentric) were used, an objective comparison could not be made because of small number. However, in another study [8], the eccentric device had fewer complications when compared with a concentric device. In this study, the pig with the eccentric device did not have residual shunt or aortic regurgitation, but did develop mild tricuspid insufficiency. An ideal paramembranous device will have all the qualities of Amplatzer device and possibly an uneven and shorter waist. This would prevent tilting of the device. The shorter waist will enhance endothelialization by approximating the discs to the septum.
In summary, perventricular closure of VSD is feasible in MVSD and PVSD. This approach has been successfully applied in 1 baby [7]. The procedure can be performed without CPB with little exposure. More animal studies with longer follow-up are necessary, especially for the PVSD device.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
X. Quansheng, P. Silin, Z. Zhongyun, R. Youbao, L. Shengde, C. Qian, D. Shuhua, H. Kefeng, J. Zhixian, and W. Qin Minimally invasive perventricular device closure of an isolated perimembranous ventricular septal defect with a newly designed delivery system: preliminary experience. J. Thorac. Cardiovasc. Surg., March 1, 2009; 137(3): 556 - 559. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Gan, Q. An, K. Lin, H. Tang, R. C. Lui, K. Tao, W. Pan, and Y. Shi Perventricular Device Closure of Ventricular Septal Defects: Six Months Results in 30 Young Children Ann. Thorac. Surg., July 1, 2008; 86(1): 142 - 146. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. J. Zeng, S. Q. Sun, X. F. Chen, X. J. Ma, Y. H. Luo, Y. P. Lim, and L. Tao Device Closure of Perimembranous Ventricular Septal Defects With a Minimally Invasive Technique in 12 Patients Ann. Thorac. Surg., January 1, 2008; 85(1): 192 - 194. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Murakami, N. Yoshimura, H. Takahashi, H. Matsuhisa, M. Yoshida, Y. Oshima, T. Misaki, and M. Yamaguchi Closure of multiple ventricular septal defects by the felt sandwich technique: Further analysis of 36 patients. J. Thorac. Cardiovasc. Surg., August 1, 2006; 132(2): 278 - 282. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Amin, R. Woo, D. A. Danford, S. E. Froemming, V. M. Reddy, J. Lof, and D. Overman Robotically assisted perventricular closure of perimembranous ventricular septal defects: Preliminary results in Yucatan pigs J. Thorac. Cardiovasc. Surg., February 1, 2006; 131(2): 427 - 432. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Amin, D. A. Danford, J. Lof, K. F. Duncan, and S. Froemming Intraoperative device closure of perimembranous ventricular septal defects without cardiopulmonary bypass: Preliminary results with the perventricular technique J. Thorac. Cardiovasc. Surg., January 1, 2004; 127(1): 234 - 241. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |